Article Text

PDF
PTH-076 Inflammatory Bowel Disease: The Consequences of Anti-TNF Therapy in The Elderly
  1. M Ali,
  2. C McClean,
  3. Y Zou,
  4. J Goh
  1. Queen Elizabeth Hospital Birmingham, Birmingham, UK

Abstract

Introduction Existing literature regarding the efficacy and safety of anti-tumour necrosis factor (TNF) therapy in the elderly with inflammatory bowel disease (IBD) is scare and conflicting. The aim of this study is to assess the consequences of anti-TNF therapy (infliximab and adalimumab) in elderly patients with IBD.

Methods A retrospective single-centre analysis of all patients ≥50 years-old who were commenced on an anti-TNF agent for IBD between September 2013 - August 2015 was performed. Patients who received less than 2 doses were excluded. The type of anti-TNF used was recorded, and whether immunomodulators were commenced prior to anti-TNF therapy. Data on treatment efficacy, treatment failure and adverse events was collected.

Results 19/44 patients were male and 25/44 were female. The majority of patients (81.8%, 36/44) had a diagnosis of Crohn’s Disease, compared with 18.2% (8/44) with Ulcerative Colitis (UC). Results were analysed within subgroups based on age. The majority of patients (24/44, 55%) were aged 50–59, with 15/44 (34%) aged 60–69 and 4/44 (9%) aged 70–79. Treatment efficacy was measured by readmission with an IBD-flare and a requirement for surgery after being treated with anti-TNF. The rate of readmission with a flare was low across all age groups; of those aged 50–59, 8.3% (2/24) were readmitted, compared with 20% (3/15) aged 60–69 and 25% (1/4) aged 70–79. The median days for readmission following anti-TNF was >100 days. The number of patients who required surgery also represented a small proportion: 1 patient in age 50–59 band required anal stricture dilatation, and 2 patients in age 60–69 band required a subtotal colectomy and end ileostomy for UC. Adverse events were assessed by significant reactions to treatment, infections requiring hospitalisation, a malignancy presenting after treatment, and mortality. The incidence of these adverse events was low, and did not follow any pattern related to the age of the patient at treatment (Figure 1 and 2), and none of the deaths observed were directly related to IBD. 40% (6/15) of patients aged 60–69 required admission to hospital due to infection; however no patients in the age bands of 50–59 or 70+ had this outcome. The infective aetiology was diverse. The median days of presentation after starting anti-TNF was >200 days.

Conclusion Treatment efficacy, failure and the incidence of adverse events among older patients on anti-TNF therapy appears to be low and unrelated to increasing age. Our research suggests that anti-TNF therapy is an effective and safe treatment option for IBD patients aged over 50 who have failed previous immunomodulator therapy.

Reference 1 Lobaton et al. Efficacy and safety of anti-TNF therapy in elderly patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2015 Aug;42(4):441–51. doi:10.1111/apt.13294. Epub 2015 Jun 24.

Disclosure of Interest None Declared

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.